Buy Surgery Partners After Asset Sale: Cleaner Balance Sheet, High Operating Leverage, and a Tactical Entry

Hook & thesis

Surgery Partners (NASDAQ: SGRY) is a buy at current levels. The market reacted positively to a reported Idaho Falls asset divestment that reduces localized exposure and should free cash to pay down revolver borrowings or repurchase higher-cost debt. That transaction - while modest in scale versus the company's enterprise value - is timely: management has been operating in a higher-rate environment with leverage pressures, and any credible step toward net-debt reduction gets disproportionate credit for a leveraged healthcare roll-up.

At $15.85 the stock is trading well off its 52-week high of $23.44 but comfortably above the 52-week low of $11.41. Fundamentals still matter: Q2 2025 revenue printed $826.2 million (an 8.4% year-over-year increase) and the company continues to grow case volumes. Valuation across enterprise multiples - EV/EBITDA ~8.7x and EV/Sales ~1.66x - looks reasonable for a business with predictable cash conversion once leverage normalizes. This trade is a tactical buy with a clear stop and upside target tied to deleveraging and surgical volume recovery.

What Surgery Partners does and why the market should care

Surgery Partners is a healthcare services holding company focused on short-stay surgical care. The Surgical Facility segment includes ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities, and multi-specialty physician practices. The business model benefits from ongoing secular shifts toward outpatient procedures - a tailwind for ASCs driven by cost-efficiency, improved reimbursement for outpatient volumes, and the ability to perform increasingly complex procedures in outpatient settings.

Why investors should care now: the company sits in a market with structural growth drivers (an ASC market projected to expand materially over the coming decade) and has demonstrated mid-single-digit revenue expansion in recent quarters. Management’s capital moves - specifically the reported sale of the Idaho Falls asset - indicate a pragmatic focus on reducing revolving borrowings and shoring up the balance sheet while the company continues to expand case volume.

Numbers that matter

• Share price: $15.85 (current)
• Market cap: roughly $2.07 billion
• Enterprise value: about $5.60 billion
• EV/EBITDA: ~8.7x
• EV/Sales: ~1.66x; Price/Sales: ~0.61x
• Q2 2025 revenue: $826.2 million, +8.4% year-over-year
• Short interest: recent filings show ~12.95 million shares short (days to cover ~4.7 on latest average volume)
• Debt commentary: market discussion points to net debt-to-EBITDA in the neighborhood of 4.2x-4.6x in a higher-rate environment; the company priced $425 million of senior notes due 2032 in late 2025

Valuation framing

Surgery Partners trades at an EV/EBITDA multiple (~8.7x) that is modest for a stable services operator with clear growth levers (volume growth, case mix optimization, and network benefits). Price-to-sales (~0.61x) and price-to-book near 1x imply the market is valuing SGRY as a leveraged operator with execution and balance-sheet risk rather than a pure-growth story.

Put differently: if management uses proceeds from divestitures and the revolver to reduce net leverage, the multiple gap should compress. At $20.00 (our first target) the stock would imply more confidence in deleveraging and execution but still sit below prior cycle highs, leaving room to re-rate higher if case growth accelerates or M&A proves accretive.

Catalysts

• Balance-sheet cleanup from Idaho Falls divestment and redeployment of proceeds toward revolver paydown or buybacks.
• Upcoming quarterly reports that show continued revenue and case volume growth - Q3 and Q4 cadence can validate margin expansion.
• Market recognition of outpatient surgical tailwinds and execution on cost and revenue synergies across the portfolio.
• Lowered net debt-to-EBITDA metrics or favorable refinancing ahead of 2032 notes.
• Short-covering if the company posts better-than-expected operational results; short-interest has been elevated but has come down recently.

Trade plan (actionable)

Entry price: buy at $15.80. Stop: $13.50. Target: $20.00. Size this as a tactical position sized to risk appetite - the balance sheet and macro-rate backdrop are the primary tail risks.

Horizon: mid term (45 trading days). I expect the market to digest the balance-sheet improvement and for operational momentum (case volumes) to provide the earnings beats that drive a re-rate over the next 6-10 weeks. If the company delivers stronger-than-expected deleveraging or sustained margin improvement, the position can be extended to a longer holding period.

Why these levels? $15.80 is effectively recent trading interest and near the current price; it gives a favorable risk/reward given an upside to $20.00. The $13.50 stop limits downside to an amount that reflects re-testing the lower end of the range while allowing for normal intra-day volatility. $20.00 is a tactical target that prices in multiple expansion toward historical levels if leverage metrics improve and revenue growth sustains.

Technical & sentiment backdrop

Momentum indicators support a tactical entry: the 10- and 20-day SMAs are near $14.03 and $14.04 respectively, and the 50-day SMA is ~$14.80, indicating recent upside. RSI sits in the low 60s, leaving room before overbought territory. Short interest has been meaningful historically but shows signs of moderation - recent settlement reported about 12.95 million shares short with days to cover under 5 on higher two-week average volumes. That dynamic can amplify rallies if operational prints surprise to the upside.

Risks and counterarguments

• Leverage remains elevated. Net debt-to-EBITDA in the mid-4x range is a material overhang in a higher-rate environment. If the Idaho Falls divestment is small relative to total debt, leverage won’t move enough to change perceptions and SGRY could stay range-bound or gap lower on any refinancing noise.
• Execution risk on margins. Revenue growth is encouraging, but earnings have missed in past quarters. If margin pressures from network growth costs and staffing persist, EBITDA growth may lag revenue, keeping EV/EBITDA depressed.
• Recession or elective-procedure slowdown. ASCs are sensitive to procedure volumes; a macro slowdown or declines in elective procedures would hit utilization and cash flow.
• Refinancing and interest-rate risk. The company has $425 million of 2032 notes and uses revolver capacity; volatile credit markets could increase financing costs or constrain liquidity.
• High short interest and volatility. While short-interest has eased from earlier peaks, it has been elevated and can drive intraday volatility. That increases execution risk for larger entries.

Counterargument: The primary counter to this buy thesis is that a single asset sale — depending on scale — may be insufficient to materially change leverage ratios. If the sale is small relative to enterprise value and management does not aggressively use proceeds for debt paydown (opting for general corporate purposes or opportunistic M&A), then the market may view the move as cosmetic. In that case, the upside to $20.00 becomes less likely and the stock could revert to trading closer to the low end of its range.

What would change my mind

I would downgrade this trade to neutral if the company signals that proceeds from the Idaho Falls transaction will be used for non-deleveraging purposes, or if upcoming quarterly results show sustained margin erosion despite revenue growth. Conversely, I would upgrade the target and add to the position if management reports a meaningful decline in net debt-to-EBITDA (sub-4.0x), accelerates share repurchases, or posts clear, repeatable margin improvement tied to network efficiencies.

Conclusion

Surgery Partners is a buy at $15.80 for a mid-term (45 trading days) trade that targets $20.00 with a $13.50 stop. The combination of continued case-volume growth, a recent asset divestment that should help deleveraging, reasonable EV multiples, and improving technical momentum creates a favorable risk/reward. Size positions with discipline: leverage and execution risk remain non-trivial, so treat this as a tactical, event-driven opportunity rather than a no-risk long-term play.

Key metrics snapshot